Chemotherapy-Induced Nausea and Vomiting (CINV) Clinical Trial
Official title:
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of Intravenous Fosaprepitant Dimeglumine for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy
This study aims to demonstrate that, when given concomitantly with a 5-hydroxytryptamine 3 (5-HT3) antagonist and a corticosteroid, a single 150 mg intravenous (IV) dose of fosaprepitant given on Day 1 is superior to the control regimen of 5-HT3 antagonist and corticosteroid only, in preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04912271 -
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
|
Phase 3 | |
| Active, not recruiting |
NCT05434663 -
Safety Study of Repeat Doses of SUSTOL in Adults
|
Phase 4 | |
| Recruiting |
NCT04472143 -
Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents
|
Phase 2 | |
| Completed |
NCT00619359 -
Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)
|
Phase 3 | |
| Completed |
NCT03204279 -
PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting
|
Phase 2 | |
| Completed |
NCT00952341 -
Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)
|
Phase 3 | |
| Completed |
NCT01111851 -
Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)
|
Phase 1 |